Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program
Emerging Infections Program

Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program

Matthew R. MooreComments to Author  and Cynthia G. Whitney
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table

Comparison of serotype-specific effectiveness of PCV7 (EIP/ABCs case–control study) (14) with that of NCKP trial (9) against invasive pneumococcal disease*

Serotype
 Vaccine effectiveness/efficacy, % (95% CI)
CDC/ABCs
 NCKP trial 2000
All PCV7 types Healthy: 96 (93–98); underlying illness: 81 (57–92) 94 (80–98)
4 93 (65–99) NA
6B 94 (77–98) 86 (−11 to 100)
9V 100 (88–100) 100 (−142 to 100)
14 94 (81–98) 100 (60–100)
18C 97 (85–99) 100 (49–100)
19F 87 (65–95) 85 (32–98)
23F 98 (80–100) 100 (15–100)

*PCV7, 7-valent pneumococcal conjugate vaccine; EIP, Emerging Infections Program; ABCs, Active Bacterial Core Surveillance; NCKP, Northern California Kaiser Permanente; CDC, Centers for Disease Control and Prevention; NA, not available.

Main Article

References
  1. World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. 2013 [cited 2015 Feb 11]. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/
  2. Breiman  RF, Butler  JC, Tenover  FC, Elliott  JA, Facklam  RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831–5 . DOIPubMedGoogle Scholar
  3. Langley  G, Schaffner  W, Farley  MM, Lynfield  R, Bennett  NM, Reingold  R, Twenty years of Active Bacterial Core surveillance. Emerg Infect Dis. 2015;21:1520–1528.
  4. Bartlett  JG, Breiman  RF, Mandell  LA, File  TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998;26:811–38. DOIPubMedGoogle Scholar
  5. Tunkel  AR, Hartman  BJ, Kaplan  SL, Kaufman  BA, Roos  KL, Scheld  WM, Practical guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84. DOIPubMedGoogle Scholar
  6. Robinson  KA, Baughman  W, Rothrock  G, Barrett  NL, Pass  M, Lexau  C, Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–35. DOIPubMedGoogle Scholar
  7. Greene  CM, Kyaw  MH, Ray  SM, Schaffner  W, Lynfield  R, Barrett  NL, Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis. 2006;43:141–50. DOIPubMedGoogle Scholar
  8. Bridges  CB, Winquist  AG, Fukuda  K, Cox  NJ, Singleton  JA, Strikas  RA, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–38 .PubMedGoogle Scholar
  9. Black  S, Shinefield  H, Fireman  B, Lewis  E, Ray  P, Hansen  JR, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–95. DOIPubMedGoogle Scholar
  10. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–35 .PubMedGoogle Scholar
  11. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate caccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362–6. DOIPubMedGoogle Scholar
  12. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. JAMA. 2002;287:833–4. DOIPubMedGoogle Scholar
  13. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:177–8 .PubMedGoogle Scholar
  14. Whitney  CG, Pilishvili  T, Farley  MM, Schaffner  W, Craig  AS, Lynfield  R, Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet. 2006;368:1495–502. DOIPubMedGoogle Scholar
  15. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–7 .PubMedGoogle Scholar
  16. Bogaert  D, De Groot  R, Hermans  PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–54. DOIPubMedGoogle Scholar
  17. Whitney  CG, Farley  MM, Hadler  J, Harrison  LH, Bennett  NM, Lynfield  R, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–46. DOIPubMedGoogle Scholar
  18. Lexau  CA, Lynfield  R, Danila  R, Pilishvili  T, Facklam  R, Farley  MM, Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–51. DOIPubMedGoogle Scholar
  19. Ray  GT, Whitney  CG, Fireman  BH, Ciuryla  V, Black  SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25:494–501. DOIPubMedGoogle Scholar
  20. Ray  GT, Pelton  SI, Klugman  KP, Strutton  DR, Moore  MR. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine. 2009;27:6483–94. DOIPubMedGoogle Scholar
  21. Stoecker  C, Hampton  LM, Link-Gelles  R, Messonnier  ML, Zhou  F, Moore  MR. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132:e324–32. DOIPubMedGoogle Scholar
  22. Bergman  A, Hjelmgren  J, Ortqvist  A, Wisloff  T, Kristiansen  IS, Hogberg  LD, Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40:721–9. DOIPubMedGoogle Scholar
  23. Rozenbaum  MH, van Hoek  AJ, Fleming  D, Trotter  CL, Miller  E, Edmunds  WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;345:e6879. DOIPubMedGoogle Scholar
  24. Singleton  RJ, Hennessy  TW, Bulkow  LR, Hammitt  LL, Zulz  T, Hurlburt  DA, Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92. DOIPubMedGoogle Scholar
  25. Feikin  DR, Klugman  KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis. 2002;35:547–55. DOIPubMedGoogle Scholar
  26. Hampton  LM, Farley  MM, Schaffner  W, Thomas  A, Reingold  A, Harrison  LH, Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205:401–11. DOIPubMedGoogle Scholar
  27. Pai  R, Moore  MR, Pilishvili  T, Gertz  RE, Whitney  CG, Beall  B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–95. DOIPubMedGoogle Scholar
  28. Brueggemann  AB, Pai  R, Crook  D, Beall  B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168. DOIPubMedGoogle Scholar
  29. Feikin  DR, Kagucia  EW, Loo  JD, Link-Gelles  R, Puhan  MA, Cherian  T, Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517. DOIPubMedGoogle Scholar
  30. Porat  N, Benisty  R, Trefler  R, Givon-Lavi  N, Dagan  R. Clonal distribution of common pneumococcal serotypes not included in the 7-valent conjugate vaccine (PCV7): marked differences between two ethnic populations in southern Israel. J Clin Microbiol. 2012;50:3472–7. DOIPubMedGoogle Scholar
  31. Song  JH, Dagan  R, Klugman  KP, Fritzell  B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30:2728–37. DOIPubMedGoogle Scholar
  32. Hanquet  G, Valenciano  M, Simondon  F, Moren  A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31:5634–42. DOIPubMedGoogle Scholar
  33. Nuorti  JP, Whitney  CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18 .PubMedGoogle Scholar
  34. Moore  MR, Link-Gelles  R, Schaffner  W, Lynfield  R, Lexau  C, Bennett  NM, Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–9 and. DOIPubMedGoogle Scholar
  35. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61:394–5 .PubMedGoogle Scholar
  36. Cohen  AL, Harrison  LH, Farley  MM, Reingold  AL, Hadler  J, Schaffner  W, Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS. 2010;24:2253–62. DOIPubMedGoogle Scholar
  37. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–9 .PubMedGoogle Scholar
  38. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:521–4 .PubMedGoogle Scholar
  39. Tomczyk  S, Bennett  NM, Stoecker  C, Gierke  R, Moore  MR, Whitney  CG, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5 .PubMedGoogle Scholar
  40. Bonten  M, Bolkenbaas  M, Huijts  S, Webber  C, Gault  S, Gruber  W, Community-acquired pneumonia immunisation trial in adults (CAPITA) [abstract]. Pneumonia. 2014;3:95 [cited 2015 May 21]. https://pneumonia.org.au/index.php/pneumonia/pages/view/isppd

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external